Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Ruoyao Qi"'
Autor:
Rao Fu, Ruoyao Qi, Hualong Xiong, Xing Lei, Yao Jiang, Jinhang He, Feng Chen, Liang Zhang, Dekui Qiu, Yiyi Chen, Meifeng Nie, Xueran Guo, Yuhe Zhu, Jinlei Zhang, Mingxi Yue, Jiali Cao, Guosong Wang, Yuqiong Que, Mujing Fang, Yingbin Wang, Yixin Chen, Tong Cheng, Shengxiang Ge, Jun Zhang, Quan Yuan, Tianying Zhang, Ningshao Xia
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-14 (2024)
Abstract Antitumor therapies based on adoptively transferred T cells or oncolytic viruses have made significant progress in recent years, but the limited efficiency of their infiltration into solid tumors makes it difficult to achieve desired antitum
Externí odkaz:
https://doaj.org/article/db379e8169e6461d8eeff5f2470eb16d
Autor:
Guosong Wang, Jiali Cao, Mengxuan Gui, Pengfei Huang, Liang Zhang, Ruoyao Qi, Ruiqi Chen, Lina Lin, Qiangyuan Han, Yanhua Lin, Tian Chen, Peiqing He, Jian Ma, Rao Fu, Junping Hong, Qian Wu, Hai Yu, Junyu Chen, Chenghao Huang, Tianying Zhang, Quan Yuan, Jun Zhang, Yixin Chen, Ningshao Xia
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-4 (2023)
Externí odkaz:
https://doaj.org/article/84a0b7a6ec534864becc0668818708a4
Autor:
Guosong Wang, Jiali Cao, Mengxuan Gui, Pengfei Huang, Liang Zhang, Ruoyao Qi, Ruiqi Chen, Lina Lin, Qiangyuan Han, Yanhua Lin, Tian Chen, Peiqing He, Jian Ma, Rao Fu, Junping Hong, Qian Wu, Hai Yu, Junyu Chen, Chenghao Huang, Tianying Zhang, Quan Yuan, Jun Zhang, Yixin Chen, Ningshao Xia
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-22 (2023)
Abstract Background Oncolytic viruses are now well recognized as potential immunotherapeutic agents against cancer. However, the first FDA-approved oncolytic herpes simplex virus 1 (HSV-1), T-VEC, showed limited benefits in some patients in clinical
Externí odkaz:
https://doaj.org/article/34a065c1adcf4645aa9c4834dcdf3347
Autor:
Liang Zhang, Yao Jiang, Jinhang He, Junyu Chen, Ruoyao Qi, Lunzhi Yuan, Tiange Shao, Hui Zhao, Congjie Chen, Yaode Chen, Xijing Wang, Xing Lei, Qingxiang Gao, Chunlan Zhuang, Ming Zhou, Jian Ma, Wei Liu, Man Yang, Rao Fu, Yangtao Wu, Feng Chen, Hualong Xiong, Meifeng Nie, Yiyi Chen, Kun Wu, Mujin Fang, Yingbin Wang, Zizheng Zheng, Shoujie Huang, Shengxiang Ge, Shih Chin Cheng, Huachen Zhu, Tong Cheng, Quan Yuan, Ting Wu, Jun Zhang, Yixin Chen, Tianying Zhang, Changgui Li, Hai Qi, Yi Guan, Ningshao Xia
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-18 (2023)
Abstract The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and “anatomical escape” characteristics threaten the effectiveness of current coronavirus disease 2019 (COVID-19) vaccines. There is an urgent need to
Externí odkaz:
https://doaj.org/article/e3960e4523224e0888469ff72727bae6
Autor:
Ruoyao Qi, Jiali Cao, Yangtao Wu, Xing Lei, Jinhang He, Liang Zhang, Rao Fu, Feng Chen, Yingbin Wang, Tianying Zhang, Ningshao Xia, Quan Yuan
Publikováno v:
Frontiers in Microbiology, Vol 14 (2023)
Chronic infection with the hepatitis B virus (HBV) is a leading causes of liver cirrhosis and hepatocellular carcinoma. However, managing HBV treatments is challenging due to the lack of effective monotherapy. Here, we present two combination approac
Externí odkaz:
https://doaj.org/article/10554c87c36749ad9ff5325d5e57345d
Autor:
Rao Fu, Kang Ciming, Hai Yu, Min You, Ruoyao Qi, Jixian Tang, Yangfei Xian, Yang Huang, Ningshao Xia, Xinchu Xiang, Yuanzhi Chen, Yangtao Wu, Tianying Zhang, Wang Yiwen, Quan Yuan, Wenxin Luo
Publikováno v:
Antibody Therapeutics
Background We have previously obtained a mouse anti-hepatitis B surface antigen (HBsAg) antibody E6F6 with long-lasting serum HBsAg clearance effects. The E6F6 epitope-based protein CR-T3-SEQ13 (HBsAg aa 113-135) vaccination therapy in cynomolgus mon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a12b70731e14a260b2cb32675cbc1d89
https://doi.org/10.1093/abt/tbab020
https://doi.org/10.1093/abt/tbab020
Autor:
Liang Zhang, Yao Jiang, Jinhang He, Junyu Chen, Ruoyao Qi, Lunzhi Yuan, Tiange Shao, Congjie Chen, Yaode Chen, Xijing Wang, Xing Lei, Qingxiang Gao, Chunlan Zhuang, Ming Zhou, Jian Ma, Wei Liu, Man Yang, Rao Fu, Yangtao Wu, Feng Chen, Hualong Xiong, Meifeng Nie, Yiyi Chen, Kun Wu, Mujing Fang, Yingbin Wang, Zizheng Zheng, Shoujie Huang, Shengxiang Ge, Shih Chin Cheng, Huachen Zhu, Tong Cheng, Quan Yuan, Ting Wu, Jun Zhang, Yixin Chen, Tianying Zhang, Hai Qi, Yi Guan, Ningshao Xia
The emergence of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) variants and “anatomical escape” characteristics threaten the effectiveness of current coronavirus disease (COVID-19) vaccines. There is an urgent need to understand th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d7d56365b6fa20aa81fe0efa214cb8e
https://doi.org/10.1101/2022.10.03.510566
https://doi.org/10.1101/2022.10.03.510566
Autor:
Hualong Xiong, Hui Sun, Siling Wang, Lunzhi Yuan, Liqin Liu, Yuhe Zhu, Jinlei Zhang, Yang Huang, Ruoyao Qi, Yao Jiang, Jian Ma, Ming Zhou, Yue Ma, Rao Fu, Siping Yan, Mingxi Yue, Yangtao Wu, Min Wei, Yizhen Wang, Tingting Li, Yingbin Wang, Zizheng Zheng, Hai Yu, Tong Cheng, Shaowei Li, Quan Yuan, Jun Zhang, Yi Guan, Qingbing Zheng, Tianying Zhang, Ningshao Xia
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America. 119(34)
Antibody therapeutics for the treatment of COVID-19 have been highly successful. However, the recent emergence of the Omicron variant has posed a challenge, as it evades detection by most existing SARS-CoV-2 neutralizing antibodies (nAbs). Here, we s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f77d7d266dfc54d4a49ddcfcd2df455
https://pubmed.ncbi.nlm.nih.gov/36201543
https://pubmed.ncbi.nlm.nih.gov/36201543
Autor:
Hua-Long Xiong, Hui Sun, Si-Ling Wang, Lunzhi Yuan, Liqin Liu, Yuhe Zhu, Jinlei Zhang, Yang Huang, Ruoyao Qi, Yao Jiang, Jian Ma, Min Zhou, Yue Ma, Rao Fu, Siping Yan, Mingxi Yue, Yangtao Wu, Min Wei, Yi-Zhen Wang, Tingting Li, Yingbin Wang, Zi-Zheng Zheng, Hai Yu, Tong Cheng, Shaowei Li, Quan Yuan, Jun Zhang, Yi Guan, Qingbing Zheng, Tianying Zhang, Ningshao Xia
Antibody therapeutics for the treatment of COVID-19 has been highly successful while faces a challenge of the recent emergence of the Omicron variant which escapes the majority of existing SARS-CoV-2 neutralizing antibodies (nAbs). Here, we successfu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df467fa6dc913bb235e3a47e0cd9e3af
https://doi.org/10.21203/rs.3.rs-1386044/v1
https://doi.org/10.21203/rs.3.rs-1386044/v1
Autor:
Junyu Chen, Pui Wang, Lunzhi Yuan, Liang Zhang, Limin Zhang, Hui Zhao, Congjie Chen, Xijing Wang, Jinle Han, Yaode Chen, Jizong Jia, Zhen Lu, Junping Hong, Zicen Lu, Qian Wang, Rirong Chen, Ruoyao Qi, Jian Ma, Min Zhou, Huan Yu, Chunlan Zhuang, Xiaohui Liu, Qiangyuan Han, Guosong Wang, Yingying Su, Quan Yuan, Tong Cheng, Ting Wu, Xiangzhong Ye, Tianying Zhang, Changgui Li, Jun Zhang, Huachen Zhu, Yixin Chen, Honglin Chen, Ningshao Xia
Publikováno v:
Science bulletin. 67(13)
Remarkable progress has been made in developing intramuscular vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); however, they are limited with respect to eliciting local immunity in the respiratory tract, which is the pri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d1d4fd67c4bfcb288d09c12f6235a4c
https://pubmed.ncbi.nlm.nih.gov/35637645
https://pubmed.ncbi.nlm.nih.gov/35637645